Dynasil Announces the Nominations of Dr. Michael Joyner of the Mayo Clinic & Mr. David Kronfeld of JK & B Capital as New Dire...
December 07 2009 - 8:48AM
Business Wire
Dynasil Corporation of America (OTCBB:DYSL.OB), a rapidly
growing manufacturer of specialized instruments, detectors and
products with applications in homeland security/defense, cancer
detection, medical and industrial, today announced that Dr. Michael
Joyner of the Mayo Clinic and Mr. David Kronfeld of JK&B
Capital of Chicago have been nominated for election to the Dynasil
Board of Directors at its February 3, 2010 Annual Meeting. Dynasil
Chairman, Peter Sulick said, "It is with great pride and enthusiasm
that I look forward to welcoming these distinguished individuals to
our Board. Dynasil's 2008 acquisition of RMD Inc. brought a host of
new intellectual property ripe for commercialization into the
Company. These assets represent exciting new opportunities in
advanced scintillator design, micro crack detection, dosimeter,
photodiode design, and a number of other important growth areas for
the 21st century. Dr. Joyner and Mr. Kronfeld will bring very
specific and unique skill sets to the Dynasil Board. We expect that
their participation will help guide the Company through the
decision-making process for the commercialization of this
Intellectual Property into successful business opportunities. They
also bring a view of the future which will help focus Dynasil's
extensive and deep research capability towards areas of future
growth. Their involvement will elevate Dynasil's potential
substantially."
Michael J. Joyner, M.D. serves as the Associate Dean for
research at Mayo Clinic in Rochester, Minnesota where he also is
Deputy Director for Research, associate program director of the
Center of Translational Science Activities and a consultant to the
Department of Anesthesiology. He also holds the prestigious Frank
R. and Shari Caywood Professorship. He received his undergraduate
and medical degrees from the University of Arizona. Dr. Joyner's
work has been funded continuously by NIH since the early 1990s. He
has held important editorial positions for key journals, served as
an NIH study section member, and received numerous national and
international awards for his work on muscle blood flow and human
physiology. A number of Dr. Joyner's former fellows now direct
independent research programs in the US, Canada, Europe and
Japan.
Mr. Kronfeld founded JK&B Capital, a venture capital firm
focused in the software, IT and communications markets with over
$1.1 billion of cumulative capital under management. Mr. Kronfeld
is an experienced venture capital investor and telecommunications
industry executive with over 30 years of experience. Prior to
forming JK&B, Mr. Kronfeld was a General Partner at Boston
Capital Ventures (BCV) where he focused on making venture capital
investments in telecommunications and software companies. Before
joining BCV, Mr. Kronfeld was Vice President of Acquisitions and
Venture Investments with Ameritech where he was responsible for
directing its venture capital investments in a broad array of
telecommunications-related companies and all of Ameritech's mergers
and acquisitions activities. In addition, Mr. Kronfeld was a Senior
Manager at Booz Allen & Hamilton and a Systems Analyst at
Electronic Data Systems (EDS). Mr. Kronfeld earned a Bachelor of
Science in Electrical Engineering with high honors, a Master of
Science in Computer Science from Stevens Institute of Technology,
and a Master of Business Administration from The Wharton School of
Business. He has been a director of four public and over thirty
private company boards.
Craig Dunham, Dynasil CEO added, “While we are justifiably proud
of the Company’s 645% growth over the past five years and the
returns we’ve given our shareholders, we are always looking to the
future and what steps we can take to maintain this course. By
adding the substantial talent and creativity of Dr. Joyner and Mr.
Kronfeld to our Board, we will be taking one of those steps. I’m
eager to begin working with them and continuing to grow
Dynasil.”
About Dynasil
Dynasil is a rapidly growing manufacturer of specialized
instruments and products for a broad range of applications markets
in the homeland security/defense, medical and general industrial
sectors. In addition, the Company is engaged in a significant
amount of contract research for the government and private
industry. Dynasil and its subsidiaries have operations in New
Jersey, New York and Massachusetts.
This news release may contain forward-looking statements usually
containing the words “believe,” “expect,” “plan,” “target,”
“intend” or similar expressions. These statements are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act. Future results of operations projections, and
expectations, which may relate to this release, involve certain
risks and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, the factors detailed in the Company’s Annual Report or
Form 10-KSB and in the Company’s other Securities and Exchange
Commission filings, continuation of existing market conditions and
demand for our products.
Dynasil Corp of America (CE) (USOTC:DYSL)
Historical Stock Chart
From Jun 2024 to Jul 2024
Dynasil Corp of America (CE) (USOTC:DYSL)
Historical Stock Chart
From Jul 2023 to Jul 2024